Unlike many cancer therapies, the survival advantage of the amivantamab + lazertinib combination in the MARIPOSA trial isn't static. The benefit progressively increases at 24, 36, and 42 months, suggesting a durable, long-term impact on disease control that grows with extended follow-up.

The durability of CAR-T responses is prompting a paradigm shift. With a plateau forming on survival curves, where a third of heavily pretreated patients remain relapse-free five years post-infusion, experts are now seriously discussing how to formally define a 'cure' for multiple myeloma.

The field of multiple myeloma has transformed from having few treatments to an abundance of effective drugs. The primary clinical challenge is no longer finding a therapy that works, but rather determining the optimal sequence and combination of available options, highlighting a unique form of market maturity.

With pirtobrutinib, time to next treatment often exceeds progression-free survival. This discrepancy exists because disease progression is frequently slow and asymptomatic, meaning clinicians do not need to switch therapies immediately upon seeing radiographic changes, allowing for longer treatment duration.

The Aquila study demonstrates a significant progression-free survival benefit by treating high-risk smoldering myeloma with daratumumab instead of the traditional "watch and wait" approach. This marks a major paradigm shift toward early intervention for this precursor condition, with emerging data also suggesting a potential overall survival benefit.

For older, transplant-ineligible patients, well-tolerated, long-term regimens from trials like CFIUS shift the treatment goal. Success is defined as managing myeloma so effectively that patients are more likely to die of other age-related causes, effectively outliving their cancer.

The clinical decision for newly diagnosed, transplant-ineligible myeloma patients has fundamentally shifted. Instead of determining who is eligible for a quadruplet regimen, the primary question for clinicians is now identifying the few patients who are not fit enough for this new standard of care.

Dr. Carbone argues that traditional metrics like median survival or response rate are less relevant for immunotherapies. The true measure of success is the percentage of patients alive at five or six years—the "tail of the curve"—as this indicates a durable, potentially curative, response.

Five-year follow-up from the CARTITUDE-1 trial suggests a potential cure for multiple myeloma is achievable. With roughly one-third of heavily pretreated patients remaining in remission at five years—and some confirmed as MRD-negative—the concept of a cure is now part of the operational discussion among specialists, a monumental shift for a disease long considered incurable.